The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth of the Howard Hughes Medical Institute and Stanford University, Peter Hegemann of Humboldt University of Berlin, and Georg Nagel of the University of Würzburg for their pioneering research into light-gated ion channels and the development of optogenetics. The announcement was made on Monday by the Nobel Assembly at the Karolinska Institute in Stockholm, Sweden.
The three researchers were jointly recognized for uncovering the mechanisms that enable precise control of nerve cells in the living brain using light. Their work has created a groundbreaking tool that allows scientists to activate or inhibit specific neurons by exposing them to particular wavelengths of light, thereby transforming neuroscience research and medical applications.
The discovery originated with Hegemann’s investigation of how the green alga Chlamydomonas responds to light. He identified a light-sensitive protein in the alga’s eye spot that converts light into electrical signals, enabling the organism to navigate toward light sources. Hegemann, alongside Nagel, later identified this protein as a channelrhodopsin, demonstrating that when exposed to blue light, it opens to allow ion flow and generate electrical impulses in cells.
Further experiments showed that inserting the genetic blueprint for channelrhodopsins into human or mouse kidney cells made these cells responsive to light. Building on this, Deisseroth successfully introduced channelrhodopsin genes into nerve cells of rats and mice. By delivering light through thin optic fibers, his team could precisely control neural activity, such as triggering mouse whisker movements and mapping neural circuits involved in memory formation, including fear responses.
Experts at the Karolinska Institute have noted the importance of these tools in advancing the understanding of the brain, which remains the most complex human organ with many unexplained functions. The work has allowed researchers to establish cause-and-effect relationships between neural activity and behavior, marking a significant leap beyond previous anatomical and correlational studies.
Beyond basic science, the research has spurred clinical innovation through optogenetic therapy. In a recent trial, genetic instructions for channelrhodopsins were delivered via a harmless virus into retinal cells of a patient blinded by retinitis pigmentosa. Paired with specially designed goggles that convert visual images into light pulses, the therapy partially restored the patient’s vision.
Prof Botond Roska, co-leader of the vision restoration study, welcomed the Nobel recognition as a boost for ongoing efforts to translate optogenetics into treatments that could restore sight for blind patients. Meanwhile, Anna Wedell, a member of the Nobel committee, emphasized the potential for optogenetics to illuminate neural pathways implicated in neurological disorders such as dementia, epilepsy, and addiction, opening new avenues for diagnosis and therapy.
The prize of 12 million Swedish kronor, approximately £900,000, will be shared equally among the three laureates. This marks the 117th occasion the Nobel Prize in Medicine has been awarded, continuing a legacy of groundbreaking contributions to biomedical science.